Division of Medical Entomology, Defence Research Laboratory, Tezpur, Assam, India.
Asian Pac J Trop Med. 2013 Jul;6(7):583-8. doi: 10.1016/S1995-7645(13)60101-7.
India reports the highest number of malaria cases in Southeast Asia, of which Plasmodium falciparum contribute more than half of the cases every year. North eastern states of India contribute only 3.96% of country's population but account for >10% of total reported malaria cases, 11% of Plasmodium falciparum cases and 20% of malaria related deaths annually. In India, chloroquine resistance was reported for the first time from northeast region and since then chloroquine treatment failure is being reported from many parts of the region. Increased chloroquine treatment failure has led to change of the drug policy to artemisinin combination therapy as first line of malaria treatment in the region. However, replacing chloroquine to artemisinin combination therapy has not shown significant difference in the overall malaria incidence in the region. The present review addresses the current malaria situation of northeastern region of India in the light of antimalarials drug resistance.
印度报告了东南亚地区最多的疟疾病例，其中每年由恶性疟原虫引起的疟疾病例超过一半。印度东北部各州的人口仅占全国的 3.96%，但却占总报告疟疾病例的>10%，恶性疟原虫病例的 11%和疟疾相关死亡的 20%。在印度，首次从东北部地区报告了氯喹耐药性，此后该地区许多地区都报告了氯喹治疗失败的情况。氯喹治疗失败的增加导致该地区的抗疟药物政策发生了变化，将青蒿素联合疗法作为疟疾治疗的一线药物。然而，用青蒿素联合疗法取代氯喹并没有在该地区的总体疟疾发病率方面显示出显著差异。本综述根据抗疟药物耐药性，阐述了印度东北部地区目前的疟疾情况。
